Comparison
Two nootropic peptides with radically different risk profiles. Semax is a well-studied ACTH-derived heptapeptide with decades of human use, regulatory approval in Russia, and a documented safety profile. Dihexa is an angiotensin IV derivative with extraordinary in-vitro potency at the HGF/MET receptor, no completed human clinical trials, and a mechanism involving an oncogenic signalling pathway that warrants serious caution.
Quick Answer
Semax is the more appropriate choice for most cognitive enhancement research contexts: it has human clinical data, documented safety from decades of use, a clear mechanism through BDNF and NGF upregulation, and regulatory status in Russia. Dihexa is a far more potent compound in animal models but has never been studied in humans, acts on the oncogenic HGF/MET pathway, and carries a theoretical risk profile that makes it contraindicated in anyone with a personal or family history of cancer. Potency in animal models does not translate to safety or effectiveness in humans.
| Attribute | Semax | Dihexa |
|---|---|---|
| Origin | Synthetic derivative of ACTH(4-10) extended with Pro-Gly-Pro; developed in the USSR and Russia from the 1980s | Synthetic angiotensin IV (AngIV) derivative developed at Washington State University in the 2000s |
| Mechanism | Upregulates BDNF and NGF; dopaminergic and serotonergic modulation; weak MC3R/MC4R agonism; neuroprotection via antioxidant pathways | Potentiates hepatocyte growth factor (HGF) at the MET receptor (c-Met/HGFR); indirect mechanism via inhibition of HGF inactivation enzyme |
| Potency | Moderate; effects in micromolar range in animal models; doses typically in the microgram range nasally | Reported as 10 million times more potent than BDNF in spatial memory tests in aged rats; active at femtomolar concentrations in vitro |
| Onset (animal models) | Relatively rapid; neurotrophin upregulation observed within hours to days of dosing | Reported improvements in spatial memory in aged rats after 1 to 3 days of subcutaneous administration |
| Human trial data | Multiple completed human trials; approved in Russia for ischaemic stroke and cognitive impairment | No completed human clinical trials; no published human pharmacokinetic or safety data |
| Approved use | Approved in Russia for ischaemic stroke, cognitive decline, and stress-related cognitive impairment; not approved in the West | Not approved anywhere; no regulatory status; not approved as an investigational drug in any jurisdiction |
| Safety profile | Well-tolerated in human trials; nasal irritation the most common adverse effect; decades of use in Russia without major adverse event reporting | Unknown in humans; HGF/MET mechanism is oncogenic; potential for tumour promotion in susceptible individuals; no long-term safety data of any kind |
| Administration | Intranasal (approved route); subcutaneous injection also used in research; doses typically 300 to 900 mcg intranasally | Subcutaneous injection in animal studies; transdermal also explored; no established human dose or route |
| Primary application | Neuroprotection, stroke recovery, cognitive enhancement, ADHD, anxiety, acute stress response | Cognitive enhancement (animal models only), particularly spatial memory and dementia-relevant neurodegeneration |
| Risk level | Low to moderate; established human safety data; well-tolerated at therapeutic doses | High; unknown in humans; HGF/MET oncogenic pathway; contraindicated in anyone with cancer history or elevated oncogenic risk |
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) was developed from the 1980s through the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-10, extended with a Pro-Gly-Pro C-terminal sequence that confers resistance to enzymatic degradation and extends the peptide's duration of action compared to the parent ACTH fragment. ACTH(4-10) itself was known to have cognitive-enhancing effects in animals without the adrenocortical hormonal effects of full-length ACTH; Semax was engineered to preserve and extend those central nervous system effects.
Semax acts primarily by upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), two critical neurotrophins involved in neuronal survival, synaptic plasticity, and neurogenesis. This neurotrophin upregulation mechanism is well-established and explains Semax's neuroprotective effects in ischaemic stroke models and its cognitive-enhancing properties. Additional mechanisms include modulation of dopaminergic and serotonergic systems, weak agonism at melanocortin receptors MC3R and MC4R, and antioxidant neuroprotection.
Dihexa (N-hexanoic acid-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His; formal name PNB-0408) was developed by Joseph Harding and colleagues at Washington State University in the early 2000s as part of research into angiotensin-derived cognitive enhancement. Dihexa is a metabolically stable derivative of angiotensin IV (AngIV), a C-terminal fragment of angiotensin that had been observed to enhance spatial memory in animal models. The key mechanism involves the hepatocyte growth factor (HGF) and its receptor c-Met (also called MET or HGFR). Dihexa appears to potentiate HGF activity by binding to and inhibiting HGF-inactivating enzymes, thereby increasing the availability and activity of HGF at the MET receptor.
HGF/MET signalling promotes neuronal survival, synaptogenesis, and dendritic arborisation, which explains Dihexa's dramatic effects on spatial memory in aged rats. However, the HGF/MET pathway is also strongly oncogenic: it is one of the key growth factor signalling axes involved in tumour proliferation, invasion, and metastasis. Multiple cancer types show dysregulated HGF/MET signalling, and pharmaceutical companies have invested heavily in MET inhibitors as anticancer drugs. This dual role of HGF/MET in both neuroprotection and oncogenesis is the central safety concern with Dihexa.
Semax has been studied in Russian clinical trials for ischaemic stroke, where it demonstrated neuroprotective effects and improved neurological outcomes when administered in the acute phase. It has also been investigated for transient ischaemic attacks, cognitive impairment in vascular dementia, optic nerve atrophy, and as a cognitive enhancer under stress conditions. These studies, while often conducted within the Russian regulatory framework rather than to modern Western trial standards, provide genuine human pharmacokinetic and pharmacodynamic data and decades of post-market safety experience.
The intranasal route used for Semax achieves effective central nervous system delivery by exploiting the olfactory pathway, allowing the peptide to bypass the blood-brain barrier. This is a well-established principle for small neuropeptides and has been demonstrated for Semax in human pharmacokinetic studies. The approved clinical doses (300 to 600 mcg intranasally, one to two times daily) are well-characterised with respect to tolerability.
The most frequently cited Dihexa data point is its performance in the Morris Water Maze test in aged rats, where it reportedly produced cognitive improvements comparable to or better than BDNF at concentrations 10 million times lower. This represents extraordinary potency in an in-vitro or animal model context. However, animal model potency in spatial memory tasks does not predict human cognitive effects, and femtomolar animal model potency does not predict human safety.
Dihexa has not completed any human clinical trials. There is no published human pharmacokinetic data: it is unknown how Dihexa is absorbed, distributed, metabolised, and eliminated in humans. There is no published human safety data: the risk of systemic HGF/MET pathway activation over weeks, months, or years in human subjects has never been characterised. The absence of human data is not a bureaucratic gap; it reflects the fact that Dihexa has not progressed through any regulated clinical development pathway.
The oncogenic concern is not theoretical in the abstract sense. HGF is over-expressed in many tumours. c-Met amplification or mutation is a driver oncogene in lung, gastric, renal, liver, and other cancers. A compound that potentiates HGF/MET signalling systemically could, in principle, accelerate growth of pre-existing microscopic tumour clusters or promote progression from pre-malignant to malignant states. Whether Dihexa does this in practice in humans is unknown, because it has never been studied in humans. The risk cannot be quantified; it can only be characterised as non-zero and consistent with the mechanism.
Semax is approved as a pharmaceutical drug in Russia and Ukraine for ischaemic stroke (acute treatment), cognitive decline of vascular origin, and optic nerve atrophy. It is available as a prescription nasal spray in those markets. In countries where it is not approved, it circulates as a research compound with significant informal use in nootropic communities. The adverse effect profile documented from human use is mild: nasal irritation from the intranasal formulation is the most commonly reported effect; no major organ toxicity, endocrine disruption, or serious adverse events have been attributed to Semax in the available literature.
Dihexa has no approved use anywhere in the world, no regulatory status in any jurisdiction, and no published human adverse event data of any kind. Its safety profile is entirely unknown in humans. The absence of safety data does not mean it is safe; it means the question has not been answered. From a risk-management perspective, the combination of unknown human safety and a mechanism involving an oncogenic signalling pathway represents a fundamentally different risk posture than a compound like Semax, which has documented human tolerability from decades of clinical and post-market use.
Any person with a personal history of cancer, a family history of cancer, elevated tumour marker levels, or known genetic risk factors for cancer (BRCA mutations, Lynch syndrome, others) should treat Dihexa as contraindicated given its HGF/MET mechanism. Even for individuals without known cancer risk, the absence of human data means that long-term risks cannot be assessed. This is not a risk that can be managed by lowering the dose: if the concern is systemic HGF/MET upregulation promoting subclinical tumour growth, any dose that is pharmacologically active carries the theoretical risk.
Semax is used in research and clinical contexts for several overlapping cognitive applications. For acute neuroprotection, Semax has the strongest evidence: the Russian clinical data in ischaemic stroke is supported by a mechanistically coherent basis in BDNF/NGF upregulation and antioxidant neuroprotection. For cognitive enhancement under stress or sleep deprivation, Semax has been studied in military and occupational contexts in Russia. For attention and focus, including ADHD-adjacent applications, Semax's dopaminergic modulation provides a mechanism and there is anecdotal and case report data from informal use; this application lacks controlled trial data in the West.
Dihexa's intended cognitive application in animal models is specifically oriented toward reversing severe age-related cognitive decline and dementia-relevant neurodegeneration: restoring learning and memory in aged animals whose cognitive performance resembles early dementia rather than normal aging. The spatial memory tasks where Dihexa shows extraordinary animal model potency are those where performance has substantially degraded, not tasks of normal performance optimisation. This suggests Dihexa's target application, if translated to humans, would be severe cognitive impairment rather than normal cognitive enhancement.
For general nootropic purposes in healthy or mildly cognitively challenged individuals, Semax has more applicable evidence and a far safer risk profile. For the specific goal of reversing severe dementia-like cognitive impairment, Dihexa shows the more dramatic animal model results but cannot currently be recommended for human use given the absence of any human safety data and the oncogenic pathway concern.
For most cognitive enhancement and neuroprotection research purposes, Semax is the appropriate choice. It has documented human safety, regulatory approval in at least two jurisdictions, a well-characterised mechanism, and a tolerance profile that has been established across decades of use. Its limitations are that it requires intranasal or injectable administration, its Western evidence base is less robust than Russian data, and its effects are moderate rather than transformative.
Dihexa should not currently be considered for human self-administration in a research context. The extraordinary potency claims from animal models are scientifically interesting and provide a direction for further investigation, but they do not constitute evidence of safety or efficacy in humans. The HGF/MET oncogenic pathway concern is not a speculative risk; it is mechanistically grounded and cannot be dismissed without human pharmacokinetic, pharmacodynamic, and safety data that currently do not exist.
These compounds are not interchangeable alternatives for the same use case. They are different compounds at different stages of development for somewhat different applications with radically different risk profiles. Framing the comparison as Semax versus Dihexa somewhat misrepresents the situation: one is a characterised pharmaceutical with human data; the other is an early-stage research compound that has never been studied in humans.
Semax is an ACTH-derived heptapeptide developed in Russia that upregulates BDNF and NGF, has human clinical data, is approved as a pharmaceutical drug in Russia, and has a well-established safety profile. Dihexa is a synthetic angiotensin IV derivative developed at Washington State University that potentiates HGF at the c-Met receptor, shows extreme potency in aged rat spatial memory models, has no completed human clinical trials, and involves an oncogenic signalling pathway (HGF/MET) that represents a significant theoretical safety concern in humans.
No. Semax has the substantially safer profile for human use. It has documented human tolerability from clinical trials and decades of clinical use, an established adverse effect profile (primarily nasal irritation), and a mechanism (BDNF/NGF upregulation) that does not involve oncogenic pathways. Dihexa has no human safety data of any kind, and its mechanism through HGF/MET potentiation involves an oncogenic pathway that promotes tumour growth, invasion, and metastasis in cancer. The theoretical oncological risk of systemic HGF/MET upregulation in humans is serious and cannot be quantified because Dihexa has never been studied in humans.
In animal models, Dihexa is far more potent by conventional measures: it has been reported as 10 million times more potent than BDNF in spatial memory recovery in aged rats. However, potency in animal models does not directly translate to potency or effectiveness in humans. Semax produces measurable cognitive and neuroprotective effects in humans at approved doses. Dihexa's effects in humans are completely unknown. A compound's animal model potency is a research property, not a clinical property, and should not be used to make decisions about human use.
There is no evidence for or against a combination of Semax and Dihexa in humans or animals. Given that Dihexa has no human safety data individually, its combination with other compounds carries entirely uncharacterised risks. From a mechanistic standpoint, Semax acts through neurotrophins (BDNF, NGF) and monoamine modulation, while Dihexa acts through HGF/MET; these are orthogonal pathways with no obvious pharmacodynamic interaction. However, the question of combination safety is unanswerable without human data on Dihexa alone, which does not currently exist.
No. As of the current research landscape, Dihexa has not completed any human clinical trials and has no published human pharmacokinetic, pharmacodynamic, or safety data. All of Dihexa's documented effects are from in-vitro experiments and animal models (primarily aged rats in spatial memory tasks). This is not a minor gap in the evidence base; it means that nothing is known about how Dihexa behaves in the human body, what concentrations are reached systemically, how it is cleared, or what adverse effects it may produce. The absence of human trial data fundamentally limits any safety or efficacy conclusions about Dihexa in human populations.
Related Comparisons